Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer

8 Feb 2018

Abstract excerpt

Abstract Clonal heterogeneity associated with acquired resistance presents a critical therapeutic challenge. Whole-exome sequencing of paired tumor biopsies and targeted sequencing of cell-free DNA (cfDNA) from patients with BRAFV600E colorectal cancer receiving BRAF inhibitor combinations identified 14 distinct alterations in MAPK pathway components driving acquired resistance, with as many as eight alterations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29431697
DOI: 10.1158/2159-8290.cd-17-1227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal CancerPMID 29431697Read ↗

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal CancerSemantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.Semantic proximity Read ↗

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerSemantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular Profiling and High-Content Drug Screening of Metastatic Colorectal Cancer Organoids Reveal Evolutionary Mechanisms of Pan-KRAS Inhibitor ResistanceSemantic proximity Read ↗

Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer.Semantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.Semantic proximity Read ↗

Single-cell genomics analysis reveals complex genetic interactions in an in vivo model of acquired BRAF inhibitor resistance.Semantic proximity Read ↗

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.